Movilat (Mucopolysaccharide Polysulfuric Acid Ester, Salicylic Acid)

The product contains salicylic acid, which acts as a keratolytic agent that loosens the bonds between skin cells in the outer layer, promoting exfoliation. The mucopolysaccharide polysulfuric acid ester supports the extracellular matrix and provides mild anti‑inflammatory effects, together facilitating lesion clearance and barrier repair.

The dosage of Movilat is determined by the prescribing healthcare professional based on the specific condition, severity, and treatment area. Patients should follow the prescriber’s instructions regarding the amount to apply, frequency of application, and duration of therapy.

Safety data for Movilat in pregnancy or lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their healthcare provider before using the product.

To order Movilat, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with benzoyl peroxide or topical antibiotics, Movilat combines a keratolytic (salicylic acid) with a mucopolysaccharide component that may aid skin barrier recovery. This dual action can be gentler on sensitive skin while still providing effective exfoliation, though individual response varies and should be assessed by a clinician.

Movilat should be stored at ambient temperature below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and store it in its original packaging to maintain product stability.

Movilat is applied topically to the affected skin area. Clean and dry the skin, then spread a thin layer of the product as directed by the prescriber, usually once or twice daily. Avoid contact with eyes, mucous membranes and broken skin unless specifically instructed.

Serious risks, though rare, include severe allergic reactions such as contact dermatitis, angioedema, and life‑threatening skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Immediate medical attention is required if signs of a severe reaction appear.

Individuals with known hypersensitivity to salicylic acid, mucopolysaccharide polysulfuric acid ester, or any excipients in the formulation should avoid using Movilat. It is also contraindicated on open wounds, extensive broken skin, or in patients where systemic absorption could pose a risk, such as those on anticoagulant therapy without medical supervision.